Express Healthcare
Home  »  News  »  Anthill Ventures, HCG shortlist six start-ups for Lumos Health programme

Anthill Ventures, HCG shortlist six start-ups for Lumos Health programme

0 575
Read Article

The market access programme will help selected start-ups achieve scale and raise investments

Anthill Ventures, an investment and speed scaling platform for early growth stage startups, in partnership with HealthCare Global Enterprises (HCG), the provider of cancer care in India, announced that it has shortlisted six start-ups for Lumos Health. Lumos Health is a market access programme focussed on scaling technology start-ups in healthcare and life Sciences, powered by Anthill Ventures and HCG.

The 12-month programme is designed to help startups focussed on emerging technologies in healthcare and life sciences, accelerate their business growth by providing them support and mentorship. Lumos Health will help the selected startups to raise investments, provide assistance with mentoring and regulatory approvals, increase their customer base and generate more revenues. A cohort of six start-ups that brings in exciting solutions for healthcare and life sciences has been selected out of over 120 applications received from across the world.

Speaking on the occasion, Prasad Vanga, Founder and CEO, Anthill Ventures said, “We are thrilled to work with these start-ups — Alixir, AyuRythm, BiMedis, C-Test Medicals, Kronikare, and Raybaby. We will scale them with speed to the global markets as some of them will work on real use cases, and deploy their products in real client engagements through our tailored market access programme.”

Lumos Health is focussed on scouting startups in the verticals of oncology, fertility, genomics, bioinformatics and research and diagnostics. The six selected startups have the potential to enhance the healthcare and life sciences innovation ecosystem in India. The entrepreneurs have developed solutions using key technologies such as image-based pathology, mobile health, Artificial Intelligence (AI), early detection of cancers, easy wound assessments.

Speaking at the launch event, Dr BS Ajaikumar, Chairman and CEO, HCG Enterprise said, “We have partnered with Anthill to give an opportunity to the young minds of India and across the globe to come up with their proposals. I sincerely hope that our shared enthusiasm and passion for working in the healthcare segment will result in a grand success for everyone involved.”

Anjali Ajaikumar, Program Director, Lumos Health & Vice President – Strategy & Quality, HCG Enterprise said, “Under the Lumos Programme, start-ups will enhance their product, have impactful interactions with our 30+ partner companies in both the local and global network and see how their company is making a difference in the quality of health and patient care. I am excited that Lumos is paving the way for start-ups to make a significant impact in the future of how healthcare will be delivered.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More